Cargando…

HBsAb and HBcAb Have No Significant Effect on the Progression of SLE and RA

Detalles Bibliográficos
Autores principales:	WANG, Fen, LV, Shujuan, CAI, Jingyu, ZHOU, Xianglian, ZHU, Qicui, XU, Jianhua
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Tehran University of Medical Sciences 2017
Materias:	Letter to the Editor
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5575395/ https://www.ncbi.nlm.nih.gov/pubmed/28894717

Ejemplares similares

Moderate Risk of Hepatitis B Virus Reactivation in HBsAg(−)/HBcAb(+) Carriers Receiving Rituximab for Rheumatoid Arthritis
por: Kuo, Meng Hsuan, et al.
Publicado: (2020)

Lack of evidence of viral reactivation in HBsAg-negative HBcAb-positive and HCV patients undergoing immunosuppressive therapy for psoriasis
por: Morisco, Filomena, et al.
Publicado: (2014)

Hepatitis B Reactivation in a HBsAg-Negative, HBcAb-Positive Patient Receiving Fludarabine for the Treatment of Chronic Lymphocytic Leukaemia
por: Toscanini, Federica, et al.
Publicado: (2011)

Prevalence of Cirrhosis/Advanced Fibrosis Among HBsAg-Negative and HBcAb-Positive US Adults: A Nationwide Population-Based Study
por: Huang, Shuai-Wen, et al.
Publicado: (2022)

Management of the HBV reactivation in isolated HBcAb positive patients affected with Non Hodgkin Lymphoma
por: Masarone, Mario, et al.
Publicado: (2014)

HBcAb positivity increases the risk of postoperative complications after extended hemihepatectomy for hilar cholangiocarcinoma
por: Wang, Wen‐Qiang, et al.
Publicado: (2023)

Long-Term Safety in HBsAg-Negative, HBcAb-Positive Patients with Rheumatic Diseases Receiving Maintained Steroid Therapy after Pulse Therapy
por: Lin, Ying-Cheng, et al.
Publicado: (2021)

Risk of hepatitis B reactivation in HBsAg−/HBcAb+ patients after biologic or JAK inhibitor therapy for rheumatoid arthritis: A meta‐analysis
por: Hong, Xuezhi, et al.
Publicado: (2023)

Coexistence of HBsAg and HBsAb in a difficult-to-treat chronic hepatitis B: loss of HBsAg with entecavir plus tenofovir combination
por: Galati, Giovanni, et al.
Publicado: (2014)

Hepatitis B sero-prevalence among hematology patients: importance of Anti-HbcAb and efficiency of antiviral prophylaxis
por: Kantar, Funda Ugur, et al.
Publicado: (2022)

Analysis of serum hepatitis B virus RNA levels among HBsAg and HBsAb copositive patients and its correlation with HBV DNA
por: Xiang, Yu, et al.
Publicado: (2021)

The Impact of HBV Quasispecies Features on Immune Status in HBsAg+/HBsAb+ Patients With HBV Genotype C Using Next-Generation Sequencing
por: Wang, Ying, et al.
Publicado: (2021)

The presence of baseline HBsAb-Specific B cells can predict HBsAg or HBeAg seroconversion of chronic hepatitis B on treatment
por: Yin, Shengxia, et al.
Publicado: (2023)

Hepatitis B virus infection in an HBsAb-positive lymphoma patient who received chemotherapy: A case report
por: Kang, Fu-Biao, et al.
Publicado: (2017)

The surge of HBsAb level in a HBsAg-negative ES-SCLC patient after anlotinib plus atezolizumab treatment: A case report
por: Chen, Gangjun, et al.
Publicado: (2023)

Adoptive immune transfer from donors offers Anti-HBV protection to HBsAb-negative patients after Allo-HSCT
por: Ren, Jinhua, et al.
Publicado: (2023)

HBcAb seropositivity is correlated with poor HIV viremia control in an Italian cohort of HIV/HBV-coinfected patients on first-line therapy
por: Malagnino, Vincenzo, et al.
Publicado: (2019)

Baseline quantitative HBcAb strongly predicts undetectable HBV DNA and RNA in chronic hepatitis B patients treated with entecavir for 10 years
por: Zhang, Xi, et al.
Publicado: (2021)

Prevalence of HBc-Ab among HBs-Ag negative healthy blood donors in south of Iran
por: Khorami, Farhad, et al.
Publicado: (2013)

Poor CD4/CD8 ratio recovery in HBcAb-positive HIV patients with worse immune status is associated with significantly higher CD8 cell numbers
por: Malagnino, Vincenzo, et al.
Publicado: (2021)

Changes in hepatitis B virus surface antibody titer and risk of hepatitis B reactivation in HBsAg-negative/HBcAb-positive patients undergoing biologic therapy for rheumatic diseases: a prospective cohort study
por: Tien, Ya-Chih, et al.
Publicado: (2018)

Lamivudine 24-month-long prophylaxis is a safe and efficient choice for the prevention of hepatitis B virus reactivation in HBsAg-negative/HBcAb-positive patients with advanced DLBCL undergoing upfront R-CHOP-21
por: Giordano, Claudia, et al.
Publicado: (2023)

HBcAb Positivity Increases the Risk of Severe Hepatic Fibrosis Development in HIV/HCV-Positive Subjects From the ICONA Italian Cohort of HIV-Infected Patients
por: Malagnino, Vincenzo, et al.
Publicado: (2020)

HBcAb Positivity Is a Risk Factor for an Increased Detectability of HIV RNA after Switching to a Two-Drug Regimen Lamivudine-Based (2DR-3TC-Based) Treatment: Analysis of a Multicenter Italian Cohort
por: Malagnino, Vincenzo, et al.
Publicado: (2021)

Role of HBcAb Positivity in Increase of HIV-RNA Detectability after Switching to a Two-Drug Regimen Lamivudine-Based (2DR-3TC-Based) Treatment: Months 48 Results of a Multicenter Italian Cohort
por: Malagnino, Vincenzo, et al.
Publicado: (2023)

Highly Sensitive HBsAg, Anti-HBc and Anti HBsAg Titres in Early Diagnosis of HBV Reactivation in Anti-HBc-Positive Onco-Haematological Patients
por: Cerva, Carlotta, et al.
Publicado: (2022)

Evaluation of HBs-Ag and anti-HBc levels in serum and saliva of patients with hepatitis B
por: Gharavi, Matine, et al.
Publicado: (2020)

Intranasal HBsAg/HBcAg-Containing Vaccine Induces Neutralizing Anti-HBs Production in Hepatitis B Vaccine Non-Responders
por: Shiraishi, Kana, et al.
Publicado: (2023)

De novo hepatitis B surface antigen (HBsAg)-positive, core antibody (anti-HBc)-negative, hepatitis B virus infection post-liver transplant from an anti-HBc, HBsAg-negative donor
por: Bedi, Harjot K., et al.
Publicado: (2021)

Isolated Anti-HBc: Significance and Management
por: MORETTO, Florian, et al.
Publicado: (2020)

Anti-HBc: a significant host predictor of spontaneous HBsAg seroclearance in chronic hepatitis B patients - a retrospective longitudinal study
por: Kan, Karin, et al.
Publicado: (2023)

The Properties of Red Blood Cells from Patients Heterozygous for HbS and HbC (HbSC Genotype)
por: Hannemann, A., et al.
Publicado: (2011)

Prevalence of Anti-HBc Antibodies among HBsAg Negative Individuals and Its Association with Occult Hepatitis B
por: Madhavan, Anitha, et al.
Publicado: (2021)

Anti-HBs antibody status and some of its associated factors in dental health care workers in Tehran University of Medical Sciences: Anti-HBs Ab and associated factors in dental society
por: Alavian, Seyed Moayed, et al.
Publicado: (2011)

Cation Homeostasis in Red Cells From Patients With Sickle Cell Disease Heterologous for HbS and HbC (HbSC Genotype)
por: Hannemann, A., et al.
Publicado: (2015)

RE: Risk of HBV Reactivation in HBsAg Negative and Anti-HBc IgG Positive Patients Receiving Biologic Therapy
por: Ergenç, İlkay, et al.
Publicado: (2023)

Quantitative anti-HBc combined with quantitative HBsAg can predict HBsAg clearance in sequential combination therapy with PEG-IFN-α in NA-suppressed chronic hepatitis B patients
por: Wang, Wen-Xin, et al.
Publicado: (2022)

Psychologisches Privatattest über Ehepartner als Datenschutzverstoß: DSGVO Art. 9 Abs. 1–3, 15 Abs. 3 und 4, 17, 79 Abs. 1, 82 Abs. 1; BGB §§362 Abs. 1, 823 Abs. 1, 1004 Abs. 1 S. 2; StGB §203 Abs. 1 Nr. 2
Publicado: (2023)

What is ABS?
por: Autin, Bruno, et al.
Publicado: (1999)

ABS at CRYRING
por: Simonsson, A, et al.
Publicado: (1999)

Cannot write session to /tmp/vufind_sessions/sess_r8ldjmemgmv3blmpf3v931seok